Moderna Stock Price, News & Analysis (NASDAQ:MRNA)

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 3 sell ratings, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

20 analysts have issued 12-month price targets for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they anticipate the company's share price to reach $133.70 in the next twelve months. This suggests a possible upside of 66.5% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

Moderna's stock was trading at $179.62 at the beginning of 2023. Since then, MRNA stock has decreased by 55.3% and is now trading at $80.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our MRNA earnings forecast.

Moderna, Inc. (NASDAQ:MRNA) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($1.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.01) by $0.62. The business had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.37 billion. Moderna had a negative trailing twelve-month return on equity of 2.14% and a negative net margin of 38.00%.

ETFs with the largest weight of Moderna (NASDAQ:MRNA) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), VanEck Biotech ETF (BBH), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), iShares Genomics Immunology and Healthcare ETF (IDNA), ProShares Nanotechnology ETF (TINY) and iShares U.S. Tech Breakthrough Multisector ETF (TECB).

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

(MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Moderna's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (11.97%), Wellington Management Group LLP (1.47%), Morgan Stanley (1.39%), The Manufacturers Life Insurance Company (1.02%), FMR LLC (1.01%) and Banque Pictet & Cie SA (0.82%). Insiders that own company stock include Arpa Garay, David W Meline, Dustin A Moskovitz, James M Mock, Juan Andres, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks and W Don Cornwell.
View institutional ownership trends.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.